Search

Your search keyword '"Maria Teresa Pirrotta"' showing total 11 results
Start Over Author "Maria Teresa Pirrotta" Search Limiters Peer Reviewed
11 results on '"Maria Teresa Pirrotta"'

1. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Author

Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, Salvatore Palmieri, Michela Montagna, Nicola Vianelli, Luciana Marin, Margherita Cavallin, Monica Bocchia, Marzia Defina, Micaela Ippoliti, Felicetto Ferrara, Francesca Patriarca, Maria Antonietta Avanzini, Mario Regazzi, Michele Baccarani, Miriam Isola, Franca Soldano, and Renato Fanin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×109/L) and complete responses (platelet count > 100×109/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3–18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

Published
2008
Full Text
View/download PDF

2. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.

Author

Pier Paolo Piccaluga, Michele Malagola, Michela Rondoni, Mario Arpinati, Stefania Paolini, Anna Candoni, Renato Fanin, Emanuela Messa, Maria Teresa Pirrotta, Francesco Lauria, Giuseppe Visani, Daniele Alberti, Francesca Rancati, Vincenza Vinaccia, Domenico Russo, Giuseppe Saglio, Michele Baccarani, and Giovanni Martinelli

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5–44+). Non-hematologic toxicity was overall mild.

Published
2007
Full Text
View/download PDF

3. Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the 'RTL' (regional Tuscan lymphoma network)

Author

Emanuele Cencini, Ilaria Romano, Francesco Ghio, Chiara Camerini, Ilaria Bertaggia, Roberta Giachetti, Lara Mannelli, Maria Teresa Pirrotta, Giulia Lucco Navei, Manuel Ciceri, Giulia Cervetti, Emanuela Sant’Antonio, Federico Simonetti, Silvia Birtolo, Benedetta Puccini, Monica Bocchia, and Alberto Fabbri

Subjects
Hematology, General Medicine
Published
2023
Full Text
View/download PDF

4. Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)

Author

Gozzetti, Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Veronica Candi, Ludovica Pengue, Maria Livia Del Giudice, Irene Attucci, Francesca Bacchiarri, Ubaldo Occhini, Maria Teresa Pirrotta, Federico Perfetto, Monica Bocchia, and Alessandro

Subjects
amyloidosis, real-life, daratumumab, multiple myeloma
Abstract

Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells. Daratumumab has been utilized in recent years with unprecedented responses in multiple myeloma. In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function. Here, we report real-life treatment with Daratumumab in 33 AL amyloidosis patients treated within the Regional Tuscan Myeloma network at 5 centers with associated MGUS or SMM (n = 15) or symptomatic MM (n = 18). Patients were treated at relapsed/refractory disease stages (n = 29) with a median of one previous line of therapy or at diagnosis (n = 4). Daratumumab showed good efficacy, representing 60% of good hematological responses and 50% of organ responses in a real-life population of patients with an acceptable toxicity profile.

Published
2022
Full Text
View/download PDF

5. Sudden ventricular fibrillation and death during ibrutinib therapy—A case report

Author

Giulia Fontanelli, Maria Teresa Pirrotta, Carlo Milandri, Attilio Del Rosso, and P. Bernardeschi

Subjects
Response rate (survey), medicine.medical_specialty, biology, business.industry, Atrial fibrillation, Hematology, General Medicine, Disease, medicine.disease, chemistry.chemical_compound, Refractory, chemistry, Internal medicine, Ibrutinib, Ventricular fibrillation, medicine, biology.protein, Cardiology, Bruton's tyrosine kinase, Mantle cell lymphoma, business
Abstract

Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease. It increases progression-free survival, overall survival, response rate. The most frequent adverse reactions, are increased risk in of bleeding and atrial fibrillation, but several reports of more dangerous rhythm disturbances have been recently reported in literature. A case of a patient with refractory Waldenstrom's disease, who developed ventricular fibrillation while taking ibrutinib, is reported, along with a concise literature review.

Published
2019
Full Text
View/download PDF

6. Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

Author

Monica Bocchia, Alessandro Bucalossi, Alessandro Gozzetti, Marzia Defina, Francesco Lauria, Maria Teresa Pirrotta, and Francesco Forconi

Subjects
Myeloid, Male, Oncology, Pilot Projects, Severity of Illness Index, Risk Factors, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage, Humanized, Leukemia, Remission Induction, Age Factors, Antibodies, Monoclonal, Myeloid leukemia, Hematology, General Medicine, Middle Aged, Prognosis, Gemtuzumab, Fludarabine, Survival Rate, Leukemia, Myeloid, Acute, Treatment Outcome, medicine.anatomical_structure, Age Factors, Aged, Aminoglycosides, administration /&/ dosage, Antibodies, Humanized, Antibodies, administration /&/ dosage, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Feasibility Studies, Female, Humans, Idarubicin, administration /&/ dosage, Leukemia, Acute, diagnosis/drug therapy/mortality, Male, Middle Aged, Pilot Projects, Prognosis, Remission Induction, Risk Factors, Severity of Illness Index, Survival Rate, Treatment Outcome, Vidarabine, administration /&/ dosage/analogs /&/ derivatives, Female, Drug, Vidarabine, medicine.drug, medicine.medical_specialty, Gemtuzumab ozogamicin, Antibodies, Monoclonal, Humanized, Antibodies, Disease-Free Survival, Drug Administration Schedule, Dose-Response Relationship, Internal medicine, medicine, Humans, Idarubicin, Aged, Dose-Response Relationship, Drug, business.industry, Regimen, Aminoglycosides, Cytarabine, Feasibility Studies, diagnosis/drug therapy/mortality, business
Published
2007
Full Text
View/download PDF

7. Subject Index Vol. 124, 2010

Author

Christian Saure, L.G. Vuong, Huishu Chen, T.H. Terwey, Patricia Hall, Tatjana Stojakovic, David L. Diuguid, Maria Teresa Pirrotta, Junyuan Qi, Xu Ying, Rainer Haas, Masayori Hagimori, Duan Minghui, José Eduardo Krieger, Alexandre C. Pereira, Nihal Eisa, Rodolfo D. Cançado, G. Berti de Marinis, Hubert Scharnagl, Druck Reinhardt Druck Basel, Anna Challa, Lugui Qiu, Marianne Brodmann, P. le Coutre, Thomas Gary, P.G. Hemmati, Lars Galonska, Freideriki Koutsouka, Konstantinos L. Bourantas, B. Dörken, Mark Markowski, A. Girolami, Harald Froehlich, R. Arnold, Ernst Pilger, Guido Kobbe, Jiao Li, Eleftheria Hatzimichael, I. Dokal, Shuhua Yi, Li Jian, Nikolaos Chaliasos, Gang An, Paolo Bernardeschi, Anand Jillella, Yan Siyi, Satz Mengensatzproduktion, Thomas Schroeder, Zhao Yongqiang, T. Vulliamy, Masayoshi Ogasawara, Seitaro Kamiya, Peihong Zhang, Grant Lewis, Nathaniel B. Langer, S. Vettore, Franz Hafner, Carlos S. Chiattone, Elvira Maria Guerra-Shinohara, Antonios P. Vlahos, Zou Nong, Zhu Tienan, Paulo Caleb Junior Lima Santos, Alexandros Makis, Antigone Siamopoulou, Christian Weigelt, Masayuki Arakawa, Shen Ti, David L. DeRemer, Dimitrios K. Bourantas, David E. Leaf, Zhou Daobin, E. Bonamigo, Zhang Wei, George Garratty, Yaozhong Zhao, Han Bing, Dehui Zou, S. Neuburger, R. Sartori, Wang Shujie, Jun Wang, Mohamed El-Geneidy, Robin Dobbins, Viola Klärner, and Celalettin Ustun

Subjects
Index (economics), Statistics, Subject (documents), Hematology, General Medicine, Mathematics
Published
2010
Full Text
View/download PDF

8. Subject Index Vol. 117, 2007

Author

Giovanni Targher, Maria Teresa Pirrotta, Filomena Cappucci, Maria Rosaria De Cuia, Hirokazu Murakami, Nikolaos Gompakis, Vassilios Kouloulias, Hideo Koh, Takahisa Yamane, Elvira Grandone, Francisco Sicilia, Masamitsu Karasawa, Chang-Ki Min, Fabiana Gentilini, Nicola Cascavilla, Takafumi Matsushima, Younggu Kim, Takashi Okamura, Tatiana Gil Alves Portugal, Jong Weon Choi, Giuliana Alimena, Gyeongsin Park, Anna Levi, Shuichiro Nagata, Seok Lee, Kensuke Ohta, Fiammetta Natalino, Leonora Houet, Chaido Tsantali, Marina Economou, Donatella Raspadori, Maria Keramida, Rosaria Crupi, Hiroshi Handa, Kiyoyuki Hagihara, Yoshihisa Nojima, Hiroyuki Irisawa, Ivan Alvarez, Norifumi Tsukamoto, Takayuki Saitoh, Hideaki Ogata, Donatella Colaizzo, Giuseppe Lippi, Juan Espinosa, Sung-Jin Moon, Hendrik Veelken, Eijiro Oku, Myungshin Kim, Monica Bocchia, Yuka Takata, Hirohisa Nakamae, Alessandro Gozzetti, Masayuki Hino, Koichi Osaki, Jürgen Finke, Michio Sata, Akihiko Yokohama, Ritsuko Seki, Takahiko Nakane, Erina Sakamoto, Massimo Breccia, Elena Carretera, Annamaria Frustaci, Yasunobu Takeoka, Massimo Franchini, Kazuaki Yakushiji, Anna-Katharina Thomas-Kaskel, Maria Rosa Valvano, Jong Wook Lee, Gianna Maria D'Elia, Lorella Melillo, Simona Calabrese, Dong-Gun Lee, Korenori Otsubo, Masataka Sakuraya, Ki-Ryang Koh, Chun-Choo Kim, Dieter Herchenbach, Roberto Latagliata, Rie Imamura, Jose Manuel Calvo-Villas, Miranda Athanasiou-Metaxa, Francesco Lauria, Kohji Yoshimoto, Arito Yamane, Michitoshi Hashiguchi, Ida Carmosino, Woo-Sung Min, and Mika Nakamae

Subjects
Index (economics), Statistics, Subject (documents), Hematology, General Medicine, Mathematics
Published
2007
Full Text
View/download PDF

9. Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma

Author

Serena Mazzotta, Francesco Lauria, Monica Bocchia, Maria Teresa Pirrotta, Alessandro Bucalossi, Francesco Forconi, Simona Sammassimo, and Alessandro Gozzetti

Subjects
Cancer Research, Pathology, medicine.medical_specialty, analysis, Thrombotic thrombocytopenic purpura, Adenocarcinoma, Fatal Outcome, medicine, Humans, complications/pathology, Purpura, Aged, Thrombotic Thrombocytopenic, Plasma Exchange, business.industry, diagnosis/etiology, Alkaline Phosphatase, medicine.disease, Occult, Dermatology, ADAMTS13, Schistocyte, Oncology, complications/enzymology/secondary, complications/pathology, Aged, Alkaline Phosphatase, analysis, Bone Marrow Neoplasms, complications/enzymology/secondary, Fatal Outcome, Female, Humans, Plasma Exchange, Purpura, Female, Bone Marrow Neoplasms, business
Published
2005
Full Text
View/download PDF

10. Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis

Author

Maria Teresa Pirrotta, Alessandro Bucalossi, Alessandro Gozzetti, Serena Mazzotta, Francesco Lauria, Monica Bocchia, and Simona Sammassimo

Subjects
Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Deep vein, Antineoplastic Agents, Neutropenia, Gastroenterology, Leukocyte Count, Internal medicine, Humans, Medicine, Multiple myeloma, Aged, Chemotherapy, business.industry, Hematology, medicine.disease, Thrombosis, Thalidomide, Surgery, Treatment Outcome, medicine.anatomical_structure, Peripheral neuropathy, Oncology, Toxicity, Female, Multiple Myeloma, business, Agranulocytosis, medicine.drug
Abstract

Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results